Synergy of lytic phage pB23 and meropenem combination against carbapenem-resistant Acinetobacter baumannii
Antimicrobial Agents and Chemotherapy · 2024
DOI: 10.1128/aac.00448-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von Jun Luo und 8 weiteren Autor:innen. Beteiligte Einrichtung: The First College of Clinical Medical Science, China Three Gorges University, Yichang, China. Hauptthemen laut MEDLINE: Acinetobacter baumannii, Meropenem, Anti-Bacterial Agents, Carbapenems. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Phage-antibiotic combination treatment is a novel noteworthy drug delivery method in anti-infection. In the current study, we have isolated a new phage, pB23, against carbapenem-resistant Acinetobacter baumannii 2023. Synergistic antibacterial effect between phage pB23 and meropenem combination could be more stable, using moderate doses of phage (multiplicity of infection ranging from 0.1 to 1,000) based on results of in vitro antibacterial activity. Phage pB23 and meropenem combination could effectively clear mature biofilms and prevent biofilm formation of carbapenem-resistant Acinetobacter baumannii in vitro . Phage pB23 and meropenem combination also has good synergistic antibacterial effects against carbapenem-resistant Acinetobacter baumannii in different growth phases under static culture conditions. The pig skin explant model shows that phage pB23 and meropenem combination has a synergistic effect to remove bacteria from wounds ex vivo . Phage pB23 and meropenem combination also exhibited a synergistic antibacterial effect in vivo using a zebrafish infection mode. The potential promotion of phage proliferation by meropenem and the sensitivity recovery of phage-resistant bacteria to meropenem might elucidate the mechanism of the synergistic antimicrobial activity. In summary, our study illustrates that phage pB23 and meropenem combination could produce synergistic antibacterial effects against carbapenem-resistant Acinetobacter baumannii under static growth conditions. This study also demonstrates that phage-antibiotic combination will become an effective strategy to enhance antibacterial activity of individual drug and provide a new idea of the drug development for the treatment of infections due to carbapenem-resistant Acinetobacter baumannii and other multidrug-resistant bacteria.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The First College of Clinical Medical Science, China Three Gorges University, Yichang, China.
- Yichang Central People's Hospital, Yichang, China.
ORCID-Profile: Jun Luo
Zitieren
APA
Luo, J., Liu, M., Ai, W., Zheng, X., Liu, S., Huang, K., Zhang, C., Li, Q., & Luo, C. (2024). Synergy of lytic phage pB23 and meropenem combination against carbapenem-resistant Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00448-24
Vancouver
Luo J, Liu M, Ai W, Zheng X, Liu S, Huang K, et al. Synergy of lytic phage pB23 and meropenem combination against carbapenem-resistant Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.00448-24
BibTeX
@article{Luo2024,
author = {Luo, Jun and Liu, Min and Ai, Wen and Zheng, Xiaoling and Liu, Shaowei and Huang, Kuo and Zhang, Changlin and Li, Qianyuan and Luo, Chunhua},
title = {Synergy of lytic phage pB23 and meropenem combination against carbapenem-resistant Acinetobacter baumannii},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2024},
doi = {10.1128/aac.00448-24}
}
EUVIMED